Mesenchymal Stem cell therapy could beat COVID-19
In recent times under the current COVID-19 crisis scenario, severe respiratory consequences of the COVID-19 pandemic have prompted an urgent need for novel therapies to address the raising concerns.
Preventing & reversing the cytokine stroma may be the key to save the patients with severe COVID-19 pneumonia. Research in the field of Stem Cells across the globe have found Mesenchymal Stem Cells (MSCs) to possess a comprehensive powerful immunomodulatory function. The clinical outcomes, as well as changes of inflammatory & immune function levels and adverse effects of patients, were assessed for 14 days after injecting Mesenchymal Stem Cells (Dental Stem cells). Mesenchymal Stem Cells derived from Dental Pulp could cure or significantly improve the functional outcomes of patients without observed adverse effects.
The pulmonary function and symptoms of the patients showed significant improvements in 2 days after Mesenchymal Stem Cells transplantation. Most severe patients recovered and got discharged in 10 days of their treatment using these Stem Cell therapies following a rapid recovery. After treatment, the peripheral lymphocytes increased, the C-reactive protein decreased, and the over-activated cytokine-secreting immune cells CXCR3+CD4+ T cells, CXCR3+CD8+ T cells, and CXCR3+ NK cells disappeared in 3-6 days. Also, a group of CD14+ CD11c+ CD11bmid regulatory DC cell populations dramatically increased. Meanwhile, the level of TNF-α significantly decreased, while IL-10 increased in the Mesenchymal Stem Cell treatment group compared to the placebo control group.
Furthermore, the gene expression profile showed Mesenchymal Stem Cells were ACE2- and TMPRSS2- which indicated Mesenchymal stem cells (Dental pulp stem cells) are free from COVID-19 infection. Thus, the intravenous transplantation of Mesenchymal stem cells was safe and effective for treatment in patients with COVID-19 pneumonia, especially for the patients in critically severe conditions. MSCs (Mesenchymal Stem Cells) also showed great potential in patients suffering from Acute Lung Injury (ALI) & Acute Respiratory Distress Syndrome (ARDS).